“Sell an Ox”-The Price of Cure for Hepatitis C in Two Countries

Ora Paltiel, Workagegnehu Hailu, Zenahebezu Abay, Avram Mark Clarfield, Martin McKee*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Chronic hepatitis C virus (HCV) infection, associated with severe liver disease and cancer, affects 70 million people worldwide. New treatments with direct-acting-antivirals offer cure for about 95% of affected individuals; however, treatment costs may be prohibitive in both the poorest and richest nations. Opting for cure may require sacrificing essential household assets. We highlight the financial dilemmas involved, drawing parallels between Ethiopia and the United States, countries where universal health coverage does not yet exist. The World Health Organization (WHO) declaration for HCV eradication by 2030 will only become reality if universal access to efficacious and affordable treatment is guaranteed for everyone.

Original languageEnglish
Pages (from-to)229-232
Number of pages4
JournalInternational Journal of Health Policy and Management
Volume9
Issue number6
DOIs
StatePublished - Jun 2020

Bibliographical note

Publisher Copyright:
© 2020 The Author(s).

Keywords

  • Antiviral Therapy
  • Ethiopia
  • Hepatitis C
  • Out-of-Pocket Expenses
  • USA

Fingerprint

Dive into the research topics of '“Sell an Ox”-The Price of Cure for Hepatitis C in Two Countries'. Together they form a unique fingerprint.

Cite this